siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Abstract
siRNA, as a precise, specific, and highly effective gene-silencing therapy, has been extensively studied. Before reaching tumor cell targets, siRNA formulations must overcome multiple extracellular barriers, including clearance from the bloodstream, membrane impermeability, capture by the mononuclear phagocyte system (MPS), rapid renal excretion, endosomal escape, and precise recognition of target cells. These challenges limit siRNA’s clinical application. Consequently, various modifications have been applied to siRNA to enhance transfection efficiency, while researchers continue to pursue improved siRNA-targeting delivery systems. Nanotechnology offers a rational technical approach to address siRNA delivery. Nanoparticles can increase transfection efficiency while exhibiting lower cytotoxicity and reduced off-target effects. Various matrices have been employed to construct nanoparticles for targeted therapeutic delivery. This review briefly discusses siRNA nanoparticle delivery strategies, illustrates examples of various siRNA nanodelivery systems, such as lipid nanoparticles, polymeric siRNA nanoparticles, inorganic nanoparticles, hybrid nanoparticles, and conjugate-siRNA delivery systems, and introduces clinical trials of siRNA-loaded nanoparticles for cancer treatment, which can provide valuable references for further research and clinical application of siRNA nanoparticle delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Together with advances in nanoparticle-mediated siRNA delivery, these findings suggest that biologically inspired delivery systems may further enhance the therapeutic potential of nucleic acid-based radiosensitization strategies by improving intracellular delivery, protecting RNA cargo from degradation, and reducing off-target effects [109,110,111].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [111]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Cited by
Lunca, S., Morarasu, S., & Dimofte, G. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146522 · Cited by 2
“…siRNA delivery, these findings suggest that biologically inspired delivery systems may further enhance the therapeutic potential of nucleic acid-based radiosensitization strategies by improving intracellular delivery, protecting RNA cargo from degradation, and reducing off-target effects [109–111].”
Cyclodextrin platforms for siRNA delivery: turning design into new therapies
Sonje, D. P., & Wairkar, S. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.126948
Chien, Y.-T., Huang, J., Zhao, Y., Zhou, Y., Zhang, M., & Mu, Q. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167285
“Hydrophobic chemotherapeutics require stable incorporation to prevent premature release, whereas siRNA is highly hydrophilic, negatively charged, and prone to degradation and endosomal trapping [34].”
Ionizable Cholesterol‐Integrated Lipid Nanoparticles for Efficient siRNA Delivery to Solid Tumors
Kang, S., Nguyen, D., & Jon, S. (2026) · ChemMedChem · doi:10.1002/cmdc.70464
“Besides, the i‐Chol‐LNP formulation could be further optimized to achieve tissue‐specific tropism, expanding applications of RNAi therapy in nonon‐ cology fields such as genetic disorders and inflammatory diseases [28–30].”
Metadata
- Authors
- Wang, P., Gong, J., Xu, Y., & Xia, X.
- Affiliations
- Hunan University of Traditional Chinese Medicine (CN)
- Corresponding author
- Xia, Xinhua
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-03-26
- Volume
- 27
- Issue
- 7
- Pages
- 3032
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13073686
- OpenAlex
- W7140659748
- Cited by
- 4
- References
- 150
- Citations by year
- 2026: 4
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Science Foundation of China https://ror.org/01h0zpd94 (81573621)
- Hunan Provincial Natural Science Foundation—Departmental Joint Fund (2025JJ80199)
- Key Research and Development Plan of Hunan Province (2017SK2122)
- Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine (202302)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- siRNA, nanoparticle delivery, lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, hybrid nanostructures, endosomal escape, transfection efficiency, siRNA modification, cancer gene therapy, clinical trials
- MeSH terms
- Nanoparticle Drug Delivery System, Animals, Clinical Trials as Topic, Humans, Neoplasms, Genetic Therapy, Drug Delivery Systems, Gene Transfer Techniques, RNA Interference, RNA, Small Interfering, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy. https://app.cochat.ai/papers/10.3390/ijms27073032
- The paper
- Wang, P., Gong, J., Xu, Y., & Xia, X. (2026). siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.